Bipartisan bill makes drugs more affordable by ensuring copay assistance counts

On November 1st, Reps. Donald McEachin (D-VA) and Rodney Davis (R-IL) introduced bipartisan legislation to ensure that copay assistance for prescription drugs are counted towards a beneficiary’s cost-sharing obligations. The “Help Ensure Lower Patient Copays Act” would ban a cruel practice implemented by insurance companies that accept a patient’s copay assistance but does not apply it to the patient’s deductible and out-of-pocket cost obligations. This leaves the patient with potentially thousands of dollars in unanticipated costs. HIV+Hep urges the bill’s swift adoption by the Congress.

We can end hepatitis C. Why aren’t we?

We have the tools to eliminate hepatitis C. We even have a Viral Hepatitis National Strategic Plan developed by the HHS that provides a roadmap to eliminate hepatitis. To our great shame, we have not dedicated sufficient resources to implement it. The White House and Congress must no longer turn a blind eye to the suffering of people living with hepatitis C. We must commit the resources necessary to end the hepatitis C epidemic.

Biden budget proposes increased funding for ending HIV

As the world marked the 40th anniversary of the CDC’s first reporting on what we now know to be AIDS, President Joe Biden proposed in his budget to continue to ramp up efforts to finally end HIV in the United States. In addition to the increase of $267 million for domestic HIV testing, prevention, and treatment programs as part of the Ending the HIV Epidemic initiative, which was announced as part of the preliminary budget, Biden proposed a $46 million increase to the Ryan White HIV/AIDS Programs and $20 million for HUD’s Housing Opportunities for Persons with AIDS program.

House Supports Significant Funding Increases for Domestic HIV Programs--Minimal Increase for Hepatitis Programs

The US House of Representatives is proposing to significantly increase funding to continue to ramp up efforts to end HIV in the United States. In addition to an increase of $245 million for domestic HIV testing, prevention, and treatment programs as part of the Ending the HIV Epidemic initiative, which matches the amount proposed in President Joe Biden’s budget, the Appropriations Committee in its FY22 Labor, HHS appropriations bill is proposing an $146 million increase to the Ryan White HIV/AIDS Program, (+$100 million over Biden’s budget) and $190 million more for NIH AIDS Research that was not included in the president’s budget. The House is only including an increase of $5 million for CDC’s hepatitis division for a total of $44.5 million.

Federal Government Issues Guidance to Insurers on Coverage of HIV Prevention Drugs

The federal government issued guidance to insurers to remind them of their obligation to cover pre-exposure prophylaxis (PrEP), which are drugs that prevent HIV, at no cost to their beneficiaries. The guidance, in the form of an FAQ, also clarifies that associated services with PrEP, such as provider visits and HIV, hepatitis, and STD testing along with other laboratory tests, must also be covered with no patient cost-sharing.

124 patient groups urge Biden administration to improve prescription drug affordability

The HIV+Hepatitis Policy Institute and American Autoimmune Related Diseases Association, in collaboration with 122 other patient and provider organizations, delivered a sign-on letter to U.S. Department of Health and Human Services Secretary Xavier Becerra that urges HHS and the Biden administration to enact policies and protections that improve prescription drug affordability for the American people.

Who We Are

Monitors policies that impact the prevention and treatment of HIV, viral hepatitis, and other health conditions in the United States.

Communicates with members of the HIV, hepatitis, and other patient group communities on key policy issues that impact their access to healthcare.

Educates policymakers and members of the media about efforts to end both HIV and hepatitis in the United States and to improve access to quality and affordable healthcare for people with or at risk of serious or chronic health conditions.

Causes We Care About, and So Should You!

HIV

Promote necessary funding, programs, and policies to end the HIV epidemic in the United States

HEPATITIS

Promote necessary funding, programs, and policies to end viral hepatitis in the United States

HEALTHCARE ACCESS

Promote necessary funding, programs, and policies to end viral hepatitis in the United States

Facebook posts by @HIV+Hep

Tweets by @HIV+Hep

Concerning the proposed @SenateApprops FY22 spending to #endHIV, @HIVHep’s Carl Schmid writes: “[It] is reassuring that Congress, in a bicameral & bipartisan fashion, is in agreement that we can & must end HIV, & are prioritizing $ ↑ for progs" to do so: https://t.co/oU4BrN0kvl.
Advisors Ask White House to Expand Private Sector Role in HIV Fight https://t.co/BG7wohIkPm
@HIVHep AARDA, & dozens of other patient groups come together to urge @HHSGov to issue regulations that protect #patients and ensure #insurers count copay assistance towards patient out-of-pocket costs and deductibles. Press release: https://t.co/O86v70u62a https://t.co/HqISdJyqao HIVHep photo
@HIVHep’s Carl Schmid writes that the @SenateApprops FY22 total funding proposes $700m to #endHIV & calls this investment “pivotal to address the ongoing disparities in the HIV epidemic, 40 years after researchers 1st discovered this infectious disease”: https://t.co/oU4BrN0kvl. https://t.co/BvF8LxbeYs HIVHep photo
Hepatitis C treatment example of innovation, market competition — and unfinished business https://t.co/K4eyuQBcEO

Pin It on Pinterest